MTL-004 – Non-small cell lung cancer (NSCLC), non-melanoma skin cancer (NMSC), bladder and peritoneal cancer – MTL-004, a potent cytotoxic agent.
There are over 1.8 million new cases of Lung Cancer each year with 80% of them being NSCLC.
MTL-004 has a short ‘range’ that directly treats the Lung Cancers via an inhalation route and it can be highly effective without damaging normal cells and is rendered harmless in the bloodstream.
To the knowledge of Morvus there is no competing product with its’ unique deliver mechanism and inherent safety features.
The global NSCLC treatment market value is forecast to increase to USD 18Bn according to business intelligence provider GBI Research.
MTL-004 is currently in late stage preclinical development requiring formulation and toxicology studies. Agreement has been reached with Strathclyde University to provide Laboratory and research personnel to accelerate the development of this highly regarded compound to early Clinical trials by 2019 at the latest.
MTL-102 – Rodenticide (Selective Rat Poison)
To be developed with the financial capital raise now proposed to new investors.
Arising from an observation that Tretazicar was converted to a very toxic ‘species’ in the liver of rats. Current rodenticides contain anti-coagulants which rats tend to develop resistance and are also toxic to other species.
A suitable and effective rodenticide would be looked upon favourably by the regulatory authorities and rapidly establish a dominant position in the market place.
The Food and Environment Research Agency (FERA) has agreed verbally to an outline proposal, at a cost, to undertake the development for Morvus. This should not demand too much administration by Morvus and when completed will also significantly enhance the Balance Sheet of the Company.
The annual worldwide market is valued at USD 500m.